Beam Therapeutics had its Relative Strength (RS) Rating upgraded from 69 to 72 Friday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their biggest climbs. See if Beam Therapeutics can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Beam Therapeutics is working on a cup with handle with a 32.29 buy point. See if it can break out in heavy trade.
Beam Therapeutics posted 0% earnings growth last quarter. Revenue increased -17%.
Beam Therapeutics holds the No. 191 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and ADMA Biologics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
